Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CBSUQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
36924655 ADC 7
|
|||||
| Synonyms |
ADC 7
Click to Show/Hide
|
|||||
| Organization |
Seoul National University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.11
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation via re-bridging.
|
|||||
ADC-specific functional property(2027 Update)
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 1.04E-10 nM |
PD-L1
|
After conjugation with MMAE, BsADC consistently maintained high avidity, with KD values of 1.04E-10 and 8.51E-10 for PD-L1 and B7-H3, respectively, underscoring the sustained binding effectiveness of BsADC.
Click to Show/Hide
|
[1]
|
| 8.51E-10 nM |
B7H3
|
After conjugation with MMAE, BsADC consistently maintained high avidity, with KD values of 1.04E-10 and 8.51E-10 for PD-L1 and B7-H3, respectively, underscoring the sustained binding effectiveness of BsADC.
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
73.56 nM
|
|||
| Method Description |
The in vitro antitumor efficacy of BsADC was assessed using the SNU899 cell.
|
||||
| In Vitro Model | Laryngeal squamous cell carcinoma, Squamous cell carcinoma of the larynx | SNU899 cells | CVCL_5105 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
115.4 nM
|
|||
| Method Description |
The in vitro antitumor efficacy of BsADC was assessed using the SNU46 cell.
|
||||
| In Vitro Model | Laryngeal squamous cell carcinoma, Squamous cell carcinoma of the larynx | SNU46 cells | CVCL_5063 | ||
References